Injectable Therapies for Regional Melanoma.

Journal Article (Journal Article;Review)

Patients with unresectable cutaneous, subcutaneous, or nodal melanoma metastases are often candidates for injectable therapies, which are attractive for ease of intralesional delivery to superficial metastases and limited systemic toxicity profiles. Injectable or intralesional therapies can be part of multifaceted treatment strategies to kill tumor directly or to alter the tumor so as to make it more sensitive to systemic therapy. Talimogene laherparepvec is the only Food and Drug Administration-approved injectable therapy currently in wide clinical use in the United States, although ongoing trials are evaluating novel intralesional agents as well as combinations with systemic therapies, particularly checkpoint inhibitors.

Full Text

Duke Authors

Cited Authors

  • Farrow, NE; Leddy, M; Landa, K; Beasley, GM

Published Date

  • July 2020

Published In

Volume / Issue

  • 29 / 3

Start / End Page

  • 433 - 444

PubMed ID

  • 32482318

Pubmed Central ID

  • PMC7274146

Electronic International Standard Serial Number (EISSN)

  • 1558-5042

Digital Object Identifier (DOI)

  • 10.1016/j.soc.2020.02.008


  • eng

Conference Location

  • United States